Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsOscar Health Soliqua Xultophy Prior Auth | OpenPay…
    Ask Trek AI about this page
    CurrentOscar HealthPolicy PG153

    Antidiabetic Agents - Soliqua, Xultophy

    Customize your policy alerts

    Sign up for Oscar Health Policy PG153 alerts

    Get alerted when Policy PG153 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This guideline governs Oscar Health prior authorization and medical-necessity review for Soliqua and Xultophy in adults with type 2 diabetes mellitus. Coverage requires age-appropriate use, specified metformin or combination-therapy criteria, and avoidance of certain concomitant incretin-based medications.

    Policy Summary
    PayerOscar Health
    PolicyAntidiabetic Agents - Soliqua, Xultophy
    Policy CodePolicy PG153
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Last ReviewApr 1, 2026
    Next Review DateN/A
    Key ActionSubmit current chart notes, relevant laboratory results, and documentation supporting the diagnosis, requested therapy, and prior formulary trials.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Covered products
    24 monthsInitial authorization
    24 monthsReauthorization
    1,500 mg/dayMetformin trial

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    HbA1c ≥7.5%
    Combination-therapy threshold

    Coverage Criteria

    Initial Therapy Criteria

    Covered when ALL of the following are met for initial clinical review.

    Initial therapy criteria

    • Age and diagnosis: The medication is age-appropriate for the member under FDA-approved indications, and the member has a diagnosis of type 2 diabetes mellitus.FDA-approved age and indication
    • ONE of the following treatment pathways

      • Metformin pathway: The member is unable to use, or has adequately tried and failed, metformin at a minimum effective dose of 1,500 milligrams daily for 90 days.1,500 mg daily for 90 days
      • Combination-therapy pathway: The member requires combination therapy and has an HbA1c of 7.5 percent or greater.HbA1c >= 7.5%
    • No prohibited concomitant therapy: The requested medication will not be used concomitantly with another GLP-1 receptor agonist, dual GIP and GLP-1 receptor agonist, DPP-4 inhibitor, or DPP-4 antidiabetic combination.

    Continuation Therapy Criteria

    Covered when ALL of the following are met for subsequent clinical review.

    Continuation therapy criteria

    • ONE of the following glycemic-benefit measures

      • HbA1c reduction: A reduction in HbA1c since initiation of therapy is documented within the past 6 months.Within the past 6 months
      • Target HbA1c attained: The member has attained target HbA1c levels.HbA1c < 7% as an example, or a target determined by the treating provider based on member-specific goals
      • Fasting plasma glucose improvement: The member has improvement in fasting plasma glucose levels since initiation of therapy.

    Coverage is not supported when Soliqua or Xultophy is used for diabetic ketoacidosis or type 1 diabetes mellitus. The combinations also must not be used with another GLP-1 receptor agonist or prandial insulin; the policy further excludes concurrent dual GIP/GLP-1 receptor agonists, DPP-4 inhibitors, and DPP-4 antidiabetic combinations.

    Use of the covered insulin/analog and incretin mimetic combinations for any indication other than the covered indication—adjunctive treatment to improve glycemic control in adults with type 2 diabetes mellitus—is considered experimental, investigational, or unproven and is not eligible for coverage.

    Insulins and insulin analogs, as well as incretin mimetic combinations, used for indications other than the covered type 2 diabetes indication are considered not medically necessary by the Plan because they are deemed experimental, investigational, or unproven.

    Clinical Thresholds and Definitions for Review

    Metformin Trial
    Minimum effective dose1,500 mg of metformin daily
    Required duration90 days
    Qualifying pathwayThe member is unable to use, or has adequately tried and failed, metformin at the minimum effective dose
    Combination-Therapy HbA1c
    HbA1c threshold7.5 percent or greater
    Therapy pathwayCombination therapy
    Qualifying criterionThe member requires combination therapy and has an A1c of 7.5 percent or greater

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Preferred-Drug Prerequisite

    Prior authorization is required for Soliqua or Xultophy. The member must be unable to use, or have tried and failed, the Plan’s preferred medication(s) before coverage is considered; non-formulary requests are also subject to Non-Formulary Products Criteria (PG069).

    • Document inability to use or an adequate trial and failure of preferred medication(s).
    • Apply Non-Formulary Products Criteria (PG069) when the requested product is non-formulary.
    Prior Authorization

    Initial Authorization Requirements

    For initial authorization, the requested product is covered only when all applicable medical-necessity criteria are met. An approval may be issued for up to 24 months.

    • The medication must be age-appropriate under its FDA-approved indications.
    • The member must have type 2 diabetes mellitus.
    • The member must meet a qualifying metformin or combination-therapy pathway.

    Product Background

    Soliqua combines the long-acting basal insulin analog insulin glargine with the GLP-1 receptor agonist lixisenatide. Xultophy combines the basal insulin analog insulin degludec with the GLP-1 receptor agonist liraglutide. Both are fixed-combination antidiabetic therapies used with diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

    Key Clinical Definitions

    Dipeptidyl Peptidase-4 Inhibitor
    Drug classOral antidiabetic drugs
    MechanismBlock the DPP-4 enzyme, which degrades incretin hormones including GLP-1 and GIP
    Clinical roleUsed primarily to manage type 2 diabetes mellitus
    Dual GIP/GLP-1 Receptor Agonist
    Drug classInjectable antidiabetic drugs
    Receptor activityCombines glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor activity
    ExampleTirzepatide, marketed as Mounjaro and Zepbound

    Initial Authorization Requirements

    Initial Authorization Criteria

    For initial review, ALL requirements must be met.

    Initial authorization

    • Age and diagnosis: The medication is age-appropriate under FDA-approved indications and the member has type 2 diabetes mellitus.
    • ONE qualifying treatment pathway

      • Metformin pathway: Unable to use, or adequately tried and failed, metformin at a minimum effective dose of 1,500 milligrams daily for 90 days.1,500 mg daily for 90 days
      • Combination-therapy pathway:

    Continuation Authorization Requirements

    Continuation Authorization Criteria

    For subsequent review, ALL continuation requirements must be met.

    Continuation authorization

    • ONE qualifying measure of glycemic benefit

      • HbA1c reduction: A reduction in HbA1c since initiation of therapy is documented within the past 6 months.Within the past 6 months
      • Target HbA1c attained: The member has attained target HbA1c levels.HbA1c < 7% as an example, or a target determined by the treating provider based on member-specific goals

    Metformin Step-Therapy Pathway

    StepRequirementAlternative pathway
    1Unable to use, or adequately tried and failed, metformin at a minimum effective dose of 1,500 mg daily for 90 days.If combination therapy is required and HbA1c is 7.5% or greater, the metformin pathway may be bypassed.

    Product-Specific Maximum Daily Doses

    Soliqua Quantity Limit
    Maximum insulin glargine dose60 units per day
    Maximum lixisenatide dose20 mcg per day
    Dose basisDose increases are based on the insulin component of the combined prefilled pen
    Xultophy Quantity Limit
    Maximum insulin degludec dose50 units per day
    Maximum liraglutide dose1.8 mg per day
    Dose basisDose increases are based on the insulin component of the combined prefilled pen
    Policy Summary
    PayerOscar Health
    PolicyAntidiabetic Agents - Soliqua, Xultophy
    Policy CodePolicy PG153
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Last ReviewApr 1, 2026
    Next Review DateN/A
    Key ActionSubmit current chart notes, relevant laboratory results, and documentation supporting the diagnosis, requested therapy, and prior formulary trials.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and Definitions for ReviewAuthorization, Documentation, and Denial RisksProduct BackgroundKey Clinical DefinitionsInitial Authorization RequirementsContinuation Authorization RequirementsMetformin Step-Therapy PathwayProduct-Specific Maximum Daily Doses
  1. No prohibited concomitant therapy: The requested medication will not be used concomitantly with another GLP-1 receptor agonist, dual GIP and GLP-1 receptor agonist, DPP-4 inhibitor, or DPP-4 antidiabetic combination.
  2. Target HbA1c
    Example targetHbA1c less than 7%
    Individualized targetThe target may be determined by the treating provider based on member-specific goals
    Continuation relevanceAttainment of target HbA1c levels is one qualifying measure of glycemic benefit
    Hypoglycemia Threshold
    Typical thresholdLess than 70 mg/dL
    DefinitionA condition characterized by abnormally low blood glucose
    Common symptomsHunger, nervousness, dizziness, confusion, and, in severe cases, unconsciousness
  3. The medication must not be used with another GLP-1 receptor agonist, dual GIP/GLP-1 receptor agonist, DPP-4 inhibitor, or DPP-4 antidiabetic combination.
  4. Prior Authorization

    Reauthorization Requirements

    Reauthorization requires documented clinical benefit and continued compliance with the non-combination requirement. When all subsequent-review criteria are met, the requested product may be authorized for up to 24 months.

    • Document HbA1c reduction, attainment of the member’s target HbA1c, or improvement in fasting plasma glucose since therapy began.
    • Do not use concomitantly with another GLP-1 receptor agonist, dual GIP/GLP-1 receptor agonist, DPP-4 inhibitor, or DPP-4 antidiabetic combination.
    Step Therapy

    Preferred Therapy and Metformin Step

    Before requesting Soliqua or Xultophy, document the required preferred-therapy step and the member’s qualifying metformin history or combination-therapy need.

    • The member must be unable to use, or must have adequately tried and failed, metformin at a minimum effective dose of 1,500 mg daily for 90 days; or
    • If combination therapy is required, document an HbA1c of at least 7.5%.
    Documentation Required

    Clinical and Formulary-Trial Documentation

    Submit documentation supporting the diagnosis, relevant clinical findings, formulary-alternative trials, and the requested therapy. Documentation may include current chart notes, relevant laboratory or imaging results, prescription claims, and prescription receipts.

    • Include up-to-date chart notes and relevant test results or imaging reports supporting the diagnosis.
    • Include prescription claims or receipts supporting prior trials of formulary alternatives.
    • Identify the requested product and the clinical rationale for its use.
    Documentation Required

    Initial-Review Documentation

    For initial review, provide documentation that the requested medication is being used for an age-appropriate FDA-indicated purpose in a member with type 2 diabetes and that the qualifying treatment history is satisfied.

    • Document age-appropriate FDA-indicated use.
    • Document the type 2 diabetes mellitus diagnosis.
    • Document either adequate metformin trial and failure or inability to use metformin, or the combination-therapy pathway with HbA1c >= 7.5%.
    Documentation Required

    Continuation Documentation

    For continuation review, submit recent evidence of glycemic benefit since initiation of therapy. Documentation from within the past 6 months should show at least one qualifying response.

    • Reduction in HbA1c since therapy began, documented within the past 6 months.
    • Attainment of target HbA1c, such as less than 7%, or the treating provider’s member-specific target.
    • Improvement in fasting plasma glucose since therapy began.
    Denial Risk

    Initial Criteria Not Met

    Initial authorization may be denied when the request does not establish an age-appropriate FDA-indicated use, a type 2 diabetes diagnosis, or a qualifying treatment history.

    • The requested medication is not age-appropriate under FDA-approved indications.
    • The member does not have type 2 diabetes mellitus.
    • The member has not demonstrated inability to use or adequate trial and failure of metformin at 1,500 mg daily for 90 days, and does not meet the qualifying combination-therapy pathway with HbA1c >= 7.5%.
    Denial Risk

    Continuation Criteria Not Met

    Continuation may be denied when the member lacks documented glycemic benefit or when the requested product would be used with a prohibited concomitant therapy.

    • No documented HbA1c reduction within the past 6 months, target HbA1c attainment, or fasting-plasma-glucose improvement since initiation.
    • Concurrent use with another GLP-1 receptor agonist, dual GIP/GLP-1 receptor agonist, DPP-4 inhibitor, or DPP-4 antidiabetic combination.
    Denial Risk

    Uncovered Indications

    Use of Insulins and Analogs and Incretin Mimetic Combinations for an indication other than the covered FDA-indicated type 2 diabetes use is considered experimental, investigational, unproven, and not medically necessary by the Plan.

    • The listed products are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
    • Coverage for obesity treatment, weight loss, weight reduction, or dietary control depends on the member’s benefit policy; the Weight Loss Agents guideline (PG070) may also apply when such coverage exists.

    Unsupported block type: denial_risk

    Hemoglobin A1c
    Test typeBlood test
    What it measuresAverage blood glucose levels
    Measurement periodApproximately the past 2 to 3 months
    Hypoglycemia
    DefinitionA condition characterized by abnormally low blood glucose
    Typical thresholdLess than 70 mg/dL
    Severe-case treatmentInjectable glucagon may be used for severe cases
    Type 2 Diabetes
    DefinitionA metabolic disorder characterized by insufficient insulin production or insulin resistance in body cells
    Common managementLifestyle changes and non-insulin medications
    When necessaryInsulin injections may be used when needed
    Requires combination therapy and has an HbA1c of 7.5 percent or greater.
    HbA1c >= 7.5%
  5. No prohibited concomitant therapy: The requested medication will not be used with another GLP-1 receptor agonist, dual GIP and GLP-1 receptor agonist, DPP-4 inhibitor, or DPP-4 antidiabetic combination.
  6. Fasting plasma glucose improvement: The member has improvement in fasting plasma glucose levels since initiation of therapy.
  7. No prohibited concomitant therapy: The requested medication will not be used concomitantly with another GLP-1 receptor agonist, dual GIP and GLP-1 receptor agonist, DPP-4 inhibitor, or DPP-4 antidiabetic combination.